coramaze technologies GmbH, a German medical device company, announced the closing of a EUR 4.5 million (US$ 5.15 million) series A financing round for the mitramaze valve repair system. The device is a novel concept for transcatheter mitral valve repair (TMVR) intended for treatment of inoperable patients suffering from severe functional mitral regurgitation (fMR).

The Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center recently became the first facility in the United States to use the EpiAccess system to access the pericardial cavity of the heart during an epicardial ablation.

Medtronic received the first U.S. Food and Drug Administration (FDA) approval for an implantable cardioverter defibrillator (ICD) system for use with magnetic resonance imaging (MRI) scans. The Medtronic Evera MRI SureScan ICD System is approved for MRI scans on any part of the body without positioning restrictions, which means that patients who depend on life-saving ICDs also now have access to MRI scans if and when they need them. The newly approved system, which will be commercially available in September 2015, includes the Evera MRI ICD and Sprint Quattro Secure MRI SureScan DF4 leads, which must be used together to be considered MR-conditional.


Texas Heart Institute (THI) announced that it has received a prestigious American Heart Association grant alongside Rice University. The three-year, $750,000 grant will allow THI and Rice researchers to study and test soft, flexible fibers made of carbon nanotubes. The fibers’ ability to bridge electrical gaps in tissue is a groundbreaking discovery and offers hope to the millions of people affected by cardiac arrhythmias.


Startup cardiovascular device manufacturer Valtech Cardio Ltd. announced it has received CE Marking for its Cardioband mitral reconstruction system (Cardioband), a proprietary, implantable mitral reconstruction device with a transfemoral, transseptal delivery system for mitral valve repair.

Subscribe Now